Macrogenics (MGNX) Stock
Clinical stage biotech developing cancer antibody treatments. Here's the price, business snapshot, and what's worth knowing about Macrogenics in July 2026.
MacroGenics, Inc. (MGNX) is a small‑cap biotechnology company focused on antibody-based and bispecific immunotherapies, primarily in oncology. Investors should know the company leverages engineered Fc domains and dual‑affinity platforms to design targeted treatments; its pipeline spans preclinical to later-stage clinical programmes. As a clinical‑stage specialist with a market cap of about $127.7M, MacroGenics’ value is sensitive to trial readouts, regulatory decisions and partnership news. Biotech firms at this stage typically face significant cash burn and may need to raise capital, which can dilute shareholders. Partnerships and licensing deals can reduce commercial risk and provide non‑dilutive funding, but success depends on clinical efficacy and market adoption. This summary is educational, not personal financial advice — returns are not guaranteed and values can fall as well as rise. Investors should consider their risk tolerance and consult a regulated adviser before making decisions.
Stock Performance Snapshot
Analyst Rating
Analysts recommend buying MacroGenics' stock with a target price of $10.8, indicating strong growth potential.
Financial Health
MacroGenics is generating strong revenue and cash flow, supported by a high gross margin.
View more stocks by downloading the app for FREE
It only takes 60 seconds.
Discover More Opportunities
ACADIA PHARMACEUTICALS INC
ACADIA Pharmaceuticals Inc. is a biopharmaceutical company focused on the development and commercialization of treatments for central nervous system disorders.
ADAPTIVE BIOTECHNOLOGIES CORP
Adaptive Biotechnologies Corporation is a commercial-stage company. The Company focuses on the field of immune medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its immune medicine platform applies its technologies to read the genetic code of a patient's immune system. It operates through two segments, which include Minimal Residual Disease (MRD) and Immune Medicine. The MRD business focuses on the use of its sensitive, next-generation sequencing (NGS) assay to measure MRD in patients with hematologic malignancies. Its MRD business is comprised of its clonoSEQ clinical diagnostic testing service, offered to clinicians. Its Immune Medicine business focuses on immune-repertoire sequencing, target antigen discovery, data licensing and TCR-antigen prediction models in the identification, validation, development and adoption of products and services.
ABCELLERA BIOLOGICS INC
AbCellera Biologics Inc is a biotechnology company that provides technology to discover and develop novel fully human monoclonal antibodies.
Baskets Featuring MGNX
Pharma Stocks: Could Pipeline Power Drive Growth?
Pharmaceutical giant Roche boosted its earnings outlook, fueled by strong sales of its innovative cancer, immunology, and diagnostic products. This success highlights a broader investment opportunity in leading drugmakers with powerful research and development engines poised for growth.
Published: 23 October 2025
Explore BasketPharma M&A Targets: Biotech Stocks to Watch 2025
AbbVie is spending $2.7 billion on external R&D, highlighting a major industry trend of large pharmaceutical companies acquiring innovation. This creates a potential opportunity among the smaller biotech firms that are becoming prime acquisition targets.
Published: 5 October 2025
Explore BasketNavigating U.S. Drug Price Reforms
The White House is demanding major pharmaceutical companies slash U.S. drug prices, creating significant market volatility and threatening industry profits. This creates a potential opening for companies that offer cost-saving alternatives, such as generic drug makers and healthcare service providers.
Published: 5 August 2025
Explore BasketWhy You’ll Want to Watch This Stock
Clinical catalysts ahead
Multiple upcoming trial readouts can materially move the share price; these events are high‑impact but outcomes are binary and can be volatile.
Engineering antibodies
Fc‑engineering and bispecific platforms may create differentiated treatments, though technical and regulatory challenges remain that can delay progress.
Partnerships matter
Collaborations and licensing deals can provide funding and commercial reach, but the benefits depend on execution and market uptake.
Why invest with Nemo?
Zero Commission
Trade stocks, ETFs, and more with zero commission. Keep more of your returns.
Trusted & Regulated
Part of Exinity Group 2015, serving over a million customers globally.
6% Interest on Cash
Earn 6% AER on uninvested cash with daily interest payments.
